This study was an open-label phase I study to evaluate the safety, pharmacokinetics, and antitumor activity of SSS59 as a single agent in patients with advanced malignancies.
Histologically and/or cytologically documented local advanced or recurrent or metastatic malignancies.
Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
Expected survival >3 months.
Signed informed consent form.
Any remaining AEs > grade 1 from prior anti-tumor treatment as per CTCAE v5. 0, with exception of hair loss and fatigue.
Pregnant or nursing women or women/men who are ready to give birth.
symptomatic central nervous system metastasis.
Allergy to other antibody drugs or any excipients in the study drugs.
Shenyang Sunshine Pharmaceutical Co., LTD.
Lead sponsor